T&R Biofab
A global leader in regenerative medicine that leverages proprietary 3D bioprinting technology to develop bioresorbable medical devices, tissue-derived bio-inks, and cell-based therapeutics.
- CEO / Founder
- Won-Soo Yun
- Team Size
- 51-200
- Stage
- Established
- Total Funding
- $59.62M
- Key Investors
- Korea Investment Partners, eBest Investment & Securities, NAU IB Capital, DSC Investment, Hanbit Investment, C&Venture Partners, BTC Investment, KB Securities Co., Ltd, NH Investment & Securities Co., Ltd., Shinhan Bank, The Korea Securities Finance Corporation
Technology & Products
Key Products
Bioresorbable medical devices (e.g., cranial implants), tissue-derived bio-inks, and cell-based therapeutics.
Technological Advantage
Proprietary dECM bio-ink technology provides a biomimetic environment that outperforms synthetic alternatives in cell viability and tissue integration; maintains a vertically integrated model from bio-ink production to clinical application.
Differentiation
Value Proposition
Provides patient-specific, bioresorbable implants and organoids that minimize immune rejection and promote natural tissue regeneration, significantly improving surgical outcomes and drug development accuracy.
How They Differentiate
Extensive patent portfolio and government backing for artificial organ development
Market & Competition
Target Customers
Hospitals, medical device companies, research institutions
Industry Verticals
Bioprinting, Medical Devices, Tissue Engineering, Regenerative Medicine
Competitors
ROKIT Healthcare, CELLINK, Organovo
Growth & Milestones
Growth Metrics
$14.7M trailing 12-month revenue, $41.7M market cap (Oct 2025)
Major Milestones
Founded 2013, Series B funding, KOSDAQ listing, 8.4B won government research support, 100+ patents
Notable Customers
Ethicon (Johnson & Johnson), B. Braun Korea, CJ CheilJedang, HK inno.N